Hun Ju Lee, MD, an associate professor of medicine, Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib (Imbruvica) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). 

At the 2020 ASCO Virtual Scientific Program, findings from a phase 1b/2 trial showed that a 600 mg flat dose of cirmtuzumab plus 420 mg/day of ibrutinib in CLL and 560 mg/day in MCL was selected for part 2 of the expansion cohort.   

The combination was well tolerated, says Lee. Grade 1/2 adverse effects consisted mainly of diarrhea, confusion, and fatigue among patients with MCL or CLL.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Mantle Cell Lymphoma

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment.  This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

Hun Ju Lee, MD, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia.



Dr. Lee on Cirmtuzumab/Ibrutinib Dosing in MCL and CLL